177Lu-Edotreotide in 2026: What Phase 3 COMPETE Shows About Peptides as Precision Radiation Carriers

Evidence status: High-quality randomized Phase 3 evidence is now peer reviewed, but ¹⁷⁷Lu-edotreotide (ITM-11) remains investigational in the United States. In August 2026, FDA issued a Complete Response Letter (CRL) for its New Drug Application. According to the sponsor, the CRL cited chemistry, manufacturing and controls (CMC) and third-party facility inspection issues, with no additional clinical or nonclinical data requested. That sponsor characterization should not be confused with an FDA approval.

Why this peptide is scientifically interesting

Edotreotide is a synthetic somatostatin-receptor-targeting peptide. When linked to the beta-emitting radioisotope lutetium-177, the peptide functions as a molecular targeting vehicle: it binds somatostatin receptors that are frequently overexpressed on neuroendocrine tumor cells and carries radiation to receptor-positive tissue. This is the core idea behind peptide receptor radionuclide therapy (PRRT)—using peptide-receptor biology not simply to activate or block a pathway, but to deliver a therapeutic payload with biological selectivity.

That makes radioligand peptides an important branch of peptide science. Their value depends on several interacting variables: receptor expression, ligand affinity and internalization, radionuclide properties, absorbed dose, tumor heterogeneity, kidney and marrow exposure, manufacturing consistency, and isotope supply.

The Phase 3 COMPETE trial

The peer-reviewed COMPETE study, published in The Lancet in July 2026, was a multicenter, randomized, open-label Phase 3 superiority trial in 309 patients with advanced, progressive, grade 1 or 2 somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Participants were randomized 2:1 to ¹⁷⁷Lu-edotreotide or everolimus. The trial is registered as NCT03049189.

Protocol note: The published study used a defined radiopharmaceutical regimen under specialist clinical-trial supervision. Any doses reported in the linked trial publication or registry describe the research protocol only; they are not recommendations, dosing guidance, or instructions for use.

What the randomized evidence found

Median progression-free survival was 23.9 months with ¹⁷⁷Lu-edotreotide versus 14.1 months with everolimus. The stratified hazard ratio was 0.67 (95% CI 0.48–0.95; p=0.022). Central review also found a higher objective response rate: approximately 22% versus 4%.

The safety comparison is also notable. Treatment-related adverse events occurred in 82% of patients receiving ¹⁷⁷Lu-edotreotide and 97% receiving everolimus. Grade 3–4 treatment-related adverse events occurred in 18% versus 40%, respectively. Common treatment-related events with ¹⁷⁷Lu-edotreotide included diarrhea, nausea and asthenia. No treatment-related deaths occurred in either study group.

These results provide unusually useful evidence because COMPETE did not merely compare the radioligand with placebo. It directly compared peptide-targeted radionuclide therapy with an active molecular therapy, addressing an important question about treatment sequencing in advanced GEP-NETs.

A patient-centered signal worth following

An exploratory quality-of-life analysis presented at ASCO 2026 reported a longer time to clinically meaningful deterioration in global health status/quality of life with ¹⁷⁷Lu-edotreotide than with everolimus. Because this was an exploratory meeting analysis rather than the primary endpoint of the pivotal publication, it should be interpreted as supportive rather than definitive evidence.

The regulatory story changed in August 2026

The regulatory status is particularly important. FDA had accepted the NDA for review, but ITM announced on August 10, 2026 that it had received a Complete Response Letter dated August 7. Sponsor-reported regulatory information: ITM stated that the CRL identified CMC and third-party commercial-facility inspection items, and that FDA did not request additional clinical or nonclinical data. The product therefore remains investigational and is not FDA approved.

This distinction illustrates a broader lesson in peptide therapeutics: compelling clinical efficacy is only one component of an approvable medicine. For radiopharmaceutical peptides, reproducible manufacturing, isotope quality, facility controls and supply-chain execution can be as consequential as receptor pharmacology.

What comes next

Research is continuing beyond COMPETE. ¹⁷⁷Lu-edotreotide is also being evaluated in the Phase 3 COMPOSE program (ClinicalTrials.gov NCT04919226) in more aggressive, well-differentiated grade 2 or grade 3 somatostatin-receptor-positive GEP-NETs. Longer follow-up from COMPETE will also be important for overall survival and delayed safety outcomes.

Another promising research direction is individualized dosimetry. Sponsor-reported analyses presented at SNMMI 2026 suggest that population-based modeling might reduce the imaging burden required to estimate absorbed radiation dose. That concept is scientifically attractive, but those analyses are not equivalent to a prospective demonstration that simplified dosimetry improves clinical outcomes.

Limitations and unanswered questions

COMPETE was open label, which can influence some non-radiographic outcomes even though the primary efficacy result was based on progression assessment.
Overall-survival evidence remains less mature than the progression-free-survival result.
Results apply to the trial’s selected population of advanced, progressive, somatostatin-receptor-positive GEP-NETs and should not be generalized to tumors lacking the relevant receptor biology.
Radiopharmaceutical therapy introduces specialized radiation-safety, dosimetry, manufacturing, logistics and isotope-supply considerations that ordinary peptide pharmacology does not.
The FDA CRL means positive Phase 3 evidence has not yet translated into U.S. approval.
Exploratory subgroup, quality-of-life and dosimetry findings require appropriate caution and should not outweigh the prespecified randomized primary analysis.

Bottom line

¹⁷⁷Lu-edotreotide is a strong example of how peptide science can extend beyond conventional receptor agonists and antagonists. In COMPETE, a receptor-targeting peptide carrying lutetium-177 produced significantly longer progression-free survival than everolimus and fewer grade 3–4 treatment-related adverse events in the studied population. The result supports the broader scientific potential of peptides as precision delivery systems.

At the same time, the 2026 FDA Complete Response Letter is an equally valuable part of the story. A successful peptide medicine requires credible biology, rigorous randomized evidence, acceptable safety, and a manufacturing system capable of consistently delivering the final product. The clinical signal is encouraging; regulatory approval remains unresolved.

Sources

Editorial disclosure: This article is an independent research summary. Commercial sponsorship and sponsor-reported findings are identified separately from peer-reviewed conclusions. It is not medical advice and does not provide instructions for using research compounds or radiopharmaceuticals.